Zhi Cao

Key Laboratory Of Structure Based Drug Design And Discovery
Shenyang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Autotaxin inhibitors: an updated patent review (2021-present).

Autotaxin inhibitors: an updated patent review (2021-present).

Journal: Expert opinion on therapeutic patents

Published: July 14, 2026

Rational Optimization of Rho-Associated Coiled-Coil Containing Protein Kinase 2 Inhibitors via Disruption of Molecular Planarity for Pulmonary Fibrosis.

Rational Optimization of Rho-Associated Coiled-Coil Containing Protein Kinase 2 Inhibitors via Disruption of Molecular Planarity for Pulmonary Fibrosis.

Journal: Journal of medicinal chemistry

Published: May 25, 2026

Identification of Novel Imidazo[1,2-b]pyridazine Derivatives as Selective ROCK2 Inhibitors for the Treatment of Pulmonary Fibrosis.

Identification of Novel Imidazo[1,2-b]pyridazine Derivatives as Selective ROCK2 Inhibitors for the Treatment of Pulmonary Fibrosis.

Journal: Journal of medicinal chemistry

Published: October 03, 2025

Design and synthesis of ROCK2-selective inhibitors bearing 6-indazolamino-2-pyrrolidinylpyridine for the treatment of breast cancer metastasis.

Design and synthesis of ROCK2-selective inhibitors bearing 6-indazolamino-2-pyrrolidinylpyridine for the treatment of breast cancer metastasis.

Journal: Bioorganic chemistry

Published: May 26, 2025

Rational Design of 6-Amino-2-Piperazinylpyridine-Based ROCK2 Inhibitors With Anti-Breast Cancer Metastatic Efficiency.

Rational Design of 6-Amino-2-Piperazinylpyridine-Based ROCK2 Inhibitors With Anti-Breast Cancer Metastatic Efficiency.

Journal: Archiv der Pharmazie

Published: May 19, 2025

Discovery of novel pyrazolo[1,5-a]pyrimidine derivatives as selective ROCK2 inhibitors with anti-breast cancer migration and invasion activities.

Discovery of novel pyrazolo[1,5-a]pyrimidine derivatives as selective ROCK2 inhibitors with anti-breast cancer migration and invasion activities.

Journal: Bioorganic chemistry

Published: June 14, 2024

Discovery of first-in-class DOT1L inhibitors against the R231Q gain-of-function mutation in the catalytic domain with therapeutic potential of lung cancer.

Discovery of first-in-class DOT1L inhibitors against the R231Q gain-of-function mutation in the catalytic domain with therapeutic potential of lung cancer.

Journal: Acta pharmaceutica Sinica. B

Published: January 19, 2024

Structure-guided design of potent JAK1-selective inhibitors based on 4-amino-7H-pyrrolo[2,3-d]pyrimidine with anti-inflammatory efficacy.

Structure-guided design of potent JAK1-selective inhibitors based on 4-amino-7H-pyrrolo[2,3-d]pyrimidine with anti-inflammatory efficacy.

Journal: Archiv der Pharmazie

Published: October 13, 2023

Identification of highly potent 2,4-diarylaminopyrimidine analogs of a typical piperidinyl-4-ol moiety as promising antitumor ALK inhibitors.

Identification of highly potent 2,4-diarylaminopyrimidine analogs of a typical piperidinyl-4-ol moiety as promising antitumor ALK inhibitors.

Journal: Archiv der Pharmazie

Published: July 30, 2023

Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects.

Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects.

Journal: Bioorganic chemistry

Published: March 06, 2023

Fragment-based discovery of novel phenyltriazolyl derivatives as allosteric type-I1/2 ALK inhibitors with promising antitumor effects.

Fragment-based discovery of novel phenyltriazolyl derivatives as allosteric type-I1/2 ALK inhibitors with promising antitumor effects.

Journal: Bioorganic & medicinal chemistry letters

Published: July 21, 2022

Design, synthesis and antitumor evaluation of ATP dual-mimic 2,4-diarylaminopyrimidine and aminoindazole conjugates as potent anaplastic lymphoma kinase inhibitors.

Design, synthesis and antitumor evaluation of ATP dual-mimic 2,4-diarylaminopyrimidine and aminoindazole conjugates as potent anaplastic lymphoma kinase inhibitors.

Journal: European journal of medicinal chemistry

Published: April 29, 2022

Showing 1-12 of 16

Last Updated: 09/26/2026